Literature DB >> 32198163

Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.

David S Fedson1, Steven M Opal2, Ole Martin Rordam3.   

Abstract

Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
Copyright © 2020 Fedson et al.

Entities:  

Keywords:  COVID-19; endothelial dysfunction; generic drugs; host response treatment

Year:  2020        PMID： 32198163     DOI： 10.1128/mBio.00398-20

Source DB:  PubMed          Journal:  mBio            Impact factor:   7.867


  60 in total

Review 1.  Medication use during COVID-19: Review of recent evidence.

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

Review 2.  Commonalities Between COVID-19 and Radiation Injury.

Authors:  Carmen I Rios; David R Cassatt; Brynn A Hollingsworth; Merriline M Satyamitra; Yeabsera S Tadesse; Lanyn P Taliaferro; Thomas A Winters; Andrea L DiCarlo
Journal:  Radiat Res       Date:  2021-01-01       Impact factor: 2.841

3.  Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste.

Authors:  James T Gordy; Kaushiki Mazumdar; Noton K Dutta
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

4.  Effect of pharmaceutical regulatory policy on health impact.

Authors:  Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2020-06-14       Impact factor: 4.335

5.  Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.

Authors:  Ai-Tram N Bui; Kevin Tyan; Anita Giobbie-Hurder; Isaac A Klein; Michael P Manos; Leyre Zubiri; Kerry Reynolds; Shilpa Grover; Gerald L Weinhouse; Patrick A Ott; Nicole R LeBoeuf; Osama Rahma
Journal:  J Immunother Precis Oncol       Date:  2021-05-14

Review 6. 

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

Review 7.  Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.

Authors:  Ruirong Chen; Zhien Lan; Jujian Ye; Limin Pang; Yi Liu; Wei Wu; Xiaohuan Qin; Yang Guo; Peidong Zhang
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 7.561

8.  Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs.

Authors:  Geert Byttebier; Luc Belmans; Myriam Alexander; Bo E H Saxberg; Bart De Spiegeleer; Anton De Spiegeleer; Nick Devreker; Jens T Van Praet; Karolien Vanhove; Reinhilde Reybrouck; Evelien Wynendaele; David S Fedson
Journal:  Hum Vaccin Immunother       Date:  2021-05-28       Impact factor: 3.452

9.  Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry.

Authors:  Lori B Daniels; Junting Ren; Kris Kumar; Quan M Bui; Jing Zhang; Xinlian Zhang; Mariem A Sawan; Howard Eisen; Christopher A Longhurst; Karen Messer
Journal:  PLoS One       Date:  2021-07-15       Impact factor: 3.240

10.  Studying the Effect of Taking Statins before Infection in the Severity Reduction of COVID-19 with Machine Learning.

Authors:  Alireza Davoudi; Mohsen Ahmadi; Abbas Sharifi; Roshina Hassantabar; Narges Najafi; Atefeh Tayebi; Hamideh Abbaspour Kasgari; Fatemeh Ahmadi; Marzieh Rabiee
Journal:  Biomed Res Int       Date:  2021-06-19       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.